Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

Figure 1 Distribution of Harvey-Bradshaw index across baseline, 12 weeks, 6 months, and 12 months (boxplots represent median, interquartile range, and min-max).

Figure 2 Remission rates in risankizumab-treated Crohn’s disease patients. CD: Crohn’s disease.

Figure 3 Distribution across baseline, 12 weeks, 6 months, and 12 months (boxplots represent median, interquartile range, and min-max). A: C-reactive protein (mg/L); B: Fecal calprotectin (μg/g). CRP: C-reactive protein.

Figure 4 Probability of risankizumab drug survival expressed as a Kaplan-Meier curve with 95% confidence interval.